JPMorgan Chase & Co. Has $62.85 Million Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

JPMorgan Chase & Co. decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 86.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 572,659 shares of the medical equipment provider's stock after selling 3,767,609 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.82% of Lantheus worth $62,849,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Farallon Capital Management LLC grew its position in shares of Lantheus by 53.7% in the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider's stock valued at $182,999,000 after purchasing an additional 796,000 shares during the last quarter. Groupama Asset Managment bought a new position in Lantheus during the 3rd quarter worth $439,000. Point72 Asset Management L.P. acquired a new stake in shares of Lantheus during the second quarter worth $26,794,000. Janus Henderson Group PLC lifted its holdings in shares of Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider's stock worth $393,844,000 after buying an additional 257,022 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA bought a new stake in shares of Lantheus in the third quarter valued at about $25,955,000. 99.06% of the stock is owned by institutional investors.

Lantheus Stock Performance

Shares of LNTH traded up $2.41 during mid-day trading on Friday, reaching $91.21. The company had a trading volume of 1,116,449 shares, compared to its average volume of 943,374. The company has a market capitalization of $6.34 billion, a price-to-earnings ratio of 15.18 and a beta of 0.46. The company's 50 day simple moving average is $91.85 and its 200 day simple moving average is $99.04. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89.

Analyst Upgrades and Downgrades

Several analysts have weighed in on LNTH shares. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. Truist Financial reiterated a "buy" rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price target for the company. Finally, JMP Securities reduced their price objective on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research note on Thursday, November 7th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Lantheus has an average rating of "Moderate Buy" and an average target price of $131.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.